Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-08-12 |
2024-06 |
0 |
N/A |
N/A |
N/A |
2024-05-15 |
2024-03 |
0 |
-2.05 |
N/A |
N/A |
2024-04-01 |
2023-12 |
0 |
-2.17 |
N/A |
N/A |
2023-11-15 |
2023-09 |
0 |
-2.31 |
N/A |
N/A |
2023-08-14 |
2023-06 |
0 |
-1.2 |
N/A |
N/A |
2023-05-15 |
2023-03 |
0 |
-0.66 |
N/A |
N/A |
Date |
Name |
Relation |
Quantity |
Description |
2023-04-25 |
BERNSTEIN BRUCE T. |
Director |
8.35K |
Conversion of Exercise of derivative security |
2023-12-20 |
BOCTOR FADY |
Officer |
49.65K |
Stock Award(Grant) |
2023-04-25 |
BRADLEY GREG |
Director |
8.31K |
Conversion of Exercise of derivative security |
2020-11-30 |
GESEK ANDREW |
Officer |
0.00 |
Stock Award(Grant) |
2020-11-30 |
LAVAN KEITH |
Chief Financial Officer |
0.00 |
Stock Award(Grant) |
2021-12-21 |
SHULMAN JOHN D |
Director and Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
31.81K |
64.58K |
1.51% |
2023-06-29 |
Schonfeld Strategic Advisors Llc |
23.20K |
47.10K |
1.10% |
2023-06-29 |
Renaissance Technologies, LLC |
16.78K |
34.06K |
0.79% |
2023-06-29 |
Blackrock Inc. |
16.51K |
33.52K |
0.78% |
2023-06-29 |
Bank of Montreal/Can/ |
10.00K |
20.30K |
0.47% |
2023-06-29 |
Tower Research Capital LLC (TRC) |
2.55K |
5.17K |
0.12% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Extended Market Index Fund |
31.81K |
64.58K |
1.51% |
2023-05-30 |
Fidelity Extended Market Index Fund |
4.89K |
11.39K |
0.23% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
1.16K |
2.70K |
0.05% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
674.00 |
1.57K |
0.03% |
2023-05-30 |
Fidelity Total Market Index Fund |
110.00 |
256.00 |
0.01% |
Split |
Date |
1 : 10 |
2022-12-01 |